AAO: One Year of Valacyclovir Beneficial for Herpes Zoster Ophthalmicus

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 23, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Oct. 23, 2024 -- One year of valacyclovir is beneficial for patients with herpes zoster ophthalmicus (HZO), according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Oct. 18 to 21 in Chicago.

Elisabeth Cohen, M.D., from the NYU Grossman School of Medicine and NYU Langone Health in New York City, and colleagues conducted a multicenter, randomized controlled trial involving immunocompetent adults with HZO. A total of 527 participants were randomly assigned to suppressive valacyclovir 1,000 mg daily or placebo (266 and 261 individuals, respectively) for one year of treatment and were assessed at 18-month follow-up.

The researchers observed no significant treatment benefit in terms of reducing new/worsening stromal keratitis, iritis, dendriform epithelial keratitis, or endothelial keratitis at the primary end point of 12 months of treatment, but significant benefit was seen for the secondary end point of new or worsening eye disease at 18 months (hazard ratio, 0.74). Participants receiving valacyclovir versus placebo had a significantly lower risk for experiencing subsequent end points (i.e., multiple disease flare-ups; hazard ratios, 0.70 and 0.72 at 12 and 18 months, respectively). Participants on valacyclovir also had a significant reduction in the dose of neuropathic medications at 12 and 18 months.

"Our results support changes in clinical practice, with suppressive valacyclovir recommended to reduce new, worsening, and repeated episodes of eye disease, as well as need for neuropathic pain medication in HZO patients and in those with shingles-related pain," Cohen said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-24 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords